Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 4
1989 4
1990 9
1991 9
1992 2
1993 8
1994 6
1995 3
1996 1
1997 6
1998 7
1999 3
2000 4
2001 1
2002 2
2003 4
2004 1
2005 3
2006 2
2007 3
2008 1
2010 1
2012 3
2013 5
2014 3
2015 3
2016 1
2017 2
2018 1
2023 2
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
The pharmacokinetics of benazepril relative to other ACE inhibitors.
Gengo FM, Brady E. Gengo FM, et al. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. doi: 10.1002/clc.4960141807. Clin Cardiol. 1991. PMID: 1893642 Free article. Review.
Following oral administration, benazepril is absorbed and transformed into benazeprilat in the liver. Coadministration of benazepril with food delays absorption slightly but does not affect the ultimate bioavailability of benazeprilat. Severe hepatic impairment slow …
Following oral administration, benazepril is absorbed and transformed into benazeprilat in the liver. Coadministration of benazepril …
Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL, Lefebvre HP, King JN. Toutain PL, et al. J Pharmacol Exp Ther. 2000 Mar;292(3):1087-93. J Pharmacol Exp Ther. 2000. PMID: 10688627
The activity of benazeprilat was assessed by measuring plasma ACE inhibition with an ex vivo assay. Benazeprilat data were fitted to equations corresponding to a monocompartmental model with a volume equal to the extracellular space ( approximately 0.2 l/kg) in whic …
The activity of benazeprilat was assessed by measuring plasma ACE inhibition with an ex vivo assay. Benazeprilat data were fit …
Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Serrano-Rodríguez JM, Gómez-Díez M, Esgueva M, Castejón-Riber C, Mena-Bravo A, Priego-Capote F, Ayala N, Caballero JMS, Muñoz A. Serrano-Rodríguez JM, et al. Res Vet Sci. 2017 Oct;114:117-122. doi: 10.1016/j.rvsc.2017.03.016. Epub 2017 Mar 28. Res Vet Sci. 2017. PMID: 28371693 Clinical Trial.
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not been evaluated in horses. This study was designed to establish PK profiles for benazepril and benazeprilat after intravenous (IV) and o …
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not be …
Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King JN, Maurer M, Toutain PL. King JN, et al. J Vet Pharmacol Ther. 2003 Jun;26(3):213-24. doi: 10.1046/j.1365-2885.2003.00468.x. J Vet Pharmacol Ther. 2003. PMID: 12755906
Within this space, benazeprilat was bound nonlinearly to ACE, which was mainly tissular (89.4%) rather than circulating (10.6%). ...Nevertheless, inhibition of ACE was long-lasting (t1/2 16-23 h) due to high affinity binding of benazeprilat to ACE (Kd approximately …
Within this space, benazeprilat was bound nonlinearly to ACE, which was mainly tissular (89.4%) rather than circulating (10.6%). ...N …
Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN, Maurer M, Morrison CA, Mauron C, Kaiser G. King JN, et al. Xenobiotica. 1997 Aug;27(8):819-29. doi: 10.1080/004982597240181. Xenobiotica. 1997. PMID: 9293618
The mean residence time for benazeprilat was 15.2 h after the single dose and 17.4 h after the 14th dose. 3. Repeated administration of benazepril produced moderate bioaccumulation of benazeprilat; the ratio of AUC[0-->24 h]'s after the 14th dose as compared with …
The mean residence time for benazeprilat was 15.2 h after the single dose and 17.4 h after the 14th dose. 3. Repeated administration …
Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
Kaiser G, Ackermann R, Dieterle W, Durnin CJ, McEwen J, Ghose K, Richens A, Holmes IB. Kaiser G, et al. Eur J Clin Pharmacol. 1990;38(4):379-85. doi: 10.1007/BF00315579. Eur J Clin Pharmacol. 1990. PMID: 2344861
The elimination half-life of benazeprilat during the first 24 h after dosing in the elderly was increased by about 20% to 3.2 h. The renal plasma clearance of benazeprilat (18.1 ml.min-1) was about 20% smaller than in the young subjects. An average of 18.5% of the d …
The elimination half-life of benazeprilat during the first 24 h after dosing in the elderly was increased by about 20% to 3.2 h. The …
Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN, Mauron C, Kaiser G. King JN, et al. Am J Vet Res. 1995 Dec;56(12):1620-8. Am J Vet Res. 1995. PMID: 8599524
Plasma pharmacokinetic variables of benazeprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor benazepril, were evaluated in healthy Beagles. Benazeprilat was administered IV at a dosage of 0.5 mg/kg of body weight (n = 9). The eliminat …
Plasma pharmacokinetic variables of benazeprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor benazepr …
Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats.
Bazil MK, Webb RL. Bazil MK, et al. J Cardiovasc Pharmacol. 1993 Mar;21(3):405-11. doi: 10.1097/00005344-199303000-00009. J Cardiovasc Pharmacol. 1993. PMID: 7681501
Administration of benazeprilat (0.1-10 mg/kg i.v.) decreased arterial MAP, and benazeprilat (10 mg/kg) effectively blocked the effects of exogenously administered angiotensin I (AI). ...Simultaneous administration of amlodipine and benazeprilat produced reduc …
Administration of benazeprilat (0.1-10 mg/kg i.v.) decreased arterial MAP, and benazeprilat (10 mg/kg) effectively blocked the …
Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl.
King JN, Humbert-Droz E, Maurer M. King JN, et al. J Vet Pharmacol Ther. 1999 Dec;22(6):360-7. doi: 10.1046/j.1365-2885.1999.00230.x. J Vet Pharmacol Ther. 1999. PMID: 10651464
The plasma pharmacokinetics of benazepril and its active metabolite, benazeprilat, were determined in cats after oral administration of benazepril.HCl at dosages of 0.25, 0.5 and 1.0 mg/kg as a single dose (n = 5 per group) and after once daily application for 8 days (n = …
The plasma pharmacokinetics of benazepril and its active metabolite, benazeprilat, were determined in cats after oral administration …
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
Kitagawa H, Ohba Y, Kuwahara Y, Ohne R, Kondo M, Nakano M, Sasaki Y, Kitoh K. Kitagawa H, et al. J Vet Med Sci. 2003 Jun;65(6):701-6. doi: 10.1292/jvms.65.701. J Vet Med Sci. 2003. PMID: 12867730 Clinical Trial.
In 7 dogs with ascitic pulmonary heartworm disease, plasma benazeprilat concentrations tended to be higher than in 7 control dogs both on the 1st and 7th administration days. ...In dogs with ascitic heartworm disease, benazepril was readily transformed to benazeprilat …
In 7 dogs with ascitic pulmonary heartworm disease, plasma benazeprilat concentrations tended to be higher than in 7 control dogs bot …
104 results